BI 456906 · GLP-1 / glucagon dual agonist
Survodutide
Trial Not FDA-approved
What it is
Survodutide is an investigational dual agonist at GLP-1 and glucagon receptors. It is further along than typical catalog peptides, but research vials are not trial drug.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- A GLP-1 / glucagon dual agonist in obesity and MASH trials.
- Glucagon add-on is there to push energy use, not just appetite.
- Trial molecule. Not a research-vial twin of the drug product.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
GLP-1 activity reduces intake and improves incretin tone; glucagon-receptor activity is intended to raise energy expenditure and influence hepatic fat.
Possible side effects / caveats
GI events dominate. Titration exists in trials because jumping to maintenance is poorly tolerated. Heart-rate and gallbladder-class questions still apply.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Trial talk | About 0.6–6 mg weekly | Weekly, titrated | Order of magnitude from development programs |